What did @yenilynnn actually say?
The creator walked 104,000 viewers through reconstituting a 5mg vial of what she calls "Reza" (retatrutide, a GIP/GLP-1/glucagon triple receptor agonist) by adding 1mL of bacteriostatic water, then drawing doses using insulin syringes. She said she started at 0.5mg per week split into two injections of 0.25mg each, injecting into lower belly fat or love handles while rotating sites. She was refreshingly candid: "I get all my information from TikTok guys, just like you guys." That honesty is worth acknowledging, but it also crystallizes the problem with this video entirely.
Retatrutide is not an approved medication. It is an investigational compound currently in Phase 2 and 3 clinical trials (Jastreboff et al., 2023, NEJM). The version circulating in the peptide community comes from compounding or gray-market research chemical suppliers, with no regulatory oversight on purity, concentration, or sterility. That context is absent from this video.
Does the science back this up?
The clinical data on retatrutide is genuinely interesting, but it applies to pharmaceutical-grade, trial-controlled doses, not vials reconstituted at home using TikTok instructions. The Phase 2 trial published by Jastreboff et al. (2023, NEJM) showed meaningful weight reduction at doses escalated slowly under medical supervision, with significant gastrointestinal side effects even in that controlled setting.
On the reconstitution mechanics, the basic steps she describes are consistent with standard lyophilized peptide handling. Using bacteriostatic water is correct for multi-use vials. Angling the needle against the vial wall to avoid foaming is also a real technique. The 28-day post-reconstitution window she mentions is a commonly cited guideline for bacteriostatic water-preserved peptides, though this figure is not uniformly validated across all compounds and depends heavily on storage conditions. Calling it "supposedly" is honest at least.
The dosing math she walks through is internally consistent: 5mg in 1mL gives 5mg/mL concentration, so drawing to the 5-unit line on a 100-unit insulin syringe gives 0.25mg. The arithmetic checks out.
What did they get wrong (or right)?
Credit where it is due: the needle-angle tip, rotating injection sites to avoid lipohypertrophy, and starting at a low dose are all reasonable harm-reduction practices consistent with clinical injection guidance. Lipohypertrophy from repeated injections at the same site is a documented clinical concern (Blanco et al., 2013, Diabetes Care), and she flagged it, even if she attributed it to hearsay.
What she got wrong, or more accurately omitted, is substantial. There is no mention that retatrutide is not FDA-approved. There is no discussion of the adverse event profile documented in clinical trials, including nausea, vomiting, reduced appetite to a degree that can impair nutrition, and elevated heart rate. There is no acknowledgment that the compound she is injecting has unknown purity or sterility when sourced outside a licensed pharmacy. She credits "Chad Jibiti" (likely ChatGPT) and TikTok creators as her primary sources, which is not an appropriate foundation for injectable drug protocols. The reconstitution concentration she uses (1mL per 5mg vial) is a common community standard, but it is not derived from any approved prescribing guidance because none exists for this compound outside of clinical trials.
What should you actually know?
Retatrutide is an investigational triple agonist with early clinical data suggesting it may support significant weight reduction, but it is not approved for any use. Anyone injecting it outside of a clinical trial or a licensed telehealth prescription is using an unregulated compound with no verified quality controls. That matters because peptide vials from gray-market suppliers have been found to contain incorrect concentrations, bacterial contamination, or undisclosed substances.
The practical reconstitution steps in this video are not wildly dangerous in isolation, but presenting them without regulatory and safety context to 104,000 viewers is a meaningful omission. If you are interested in weight management pharmacotherapy, FDA-approved GLP-1 receptor agonists exist and are accessible through licensed providers. The decision to use any injectable compound should involve a clinician who knows your health history, not a TikTok comment section.
- Retatrutide is currently in Phase 3 trials and has no approved indication.
- Adverse effects in trials included nausea, vomiting, and heart rate elevation even under controlled dosing.
- Compounded or gray-market peptides carry unverified purity and sterility risks.
- The 28-day bacteriostatic water stability guideline is general practice, not compound-specific validated data.